Literature DB >> 9024154

Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease.

K Bachmaier1, C Pummerer, I Kozieradzki, K Pfeffer, T W Mak, N Neu, J M Penninger.   

Abstract

BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of myocarditis and can bind to either tumor necrosis factor receptor (TNF-R) p55 or TNF-Rp75. However, it is not known which TNF-R mediates the specific functions of TNF in disease. To determine the role of the TNF/TNF-R system in chronic heart disease, we used a murine model of cardiac myosin-induced myocarditis that closely resembles the chronic stages of virus-induced myocarditis in humans. METHODS AND
RESULTS: Mice lacking TNF-Rp55 expression after targeted disruption of the TNF-Rp55 gene were backcrossed into a genetic background susceptible to the induction of myocarditis with cardiac myosin. Here, we demonstrate that TNF-Rp55 gene-deficient mice did not develop any inflammatory infiltration into the heart after autoantigen injection, whereas control littermates showed autoimmune myocarditis at high prevalence and severity. Despite the absence of autoimmune heart disease, TNF-Rp55-/- mice produced cardiac myosin-specific IgG autoantibodies, indicating that activation of autoaggressive T and B lymphocytes had occurred. However, heart interstitial cells failed to express major histocompatibility complex (MHC) class II molecules in TNF-Rp55-/- animals, and adoptive transfer of autoreactive T cells resulted in heart disease only in TNF-Rp55-/- but not in TNF-Rp55-/- littermates.
CONCLUSIONS: Cardiac myosin-induced myocarditis is dependent on autoaggressive T cells and on autoantigen presentation in association with MHC class II molecules within the heart. Thus, lack of TNF-Rp55 expression could interfere with either lymphocyte activation or target organ susceptibility. The data presented here show that the TNF-Rp55 is a key regulator for the induction of autoimmune heart disease by its controlling target organ susceptibility.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024154     DOI: 10.1161/01.cir.95.3.655

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

Review 1.  Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis.

Authors:  M W Cunningham
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Cardiomyopathy is linked to complement activation.

Authors:  Marina Afanasyeva; Noel R Rose
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

3.  Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype.

Authors:  M Afanasyeva; Y Wang; Z Kaya; S Park; M J Zilliox; B H Schofield; S L Hill; N R Rose
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cells.

Authors:  Ya Li; Janet S Heuser; Stanley D Kosanke; Mark Hemric; Madeleine W Cunningham
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

5.  Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis.

Authors:  L McLaughlin; G Zhu; M Mistry; C Ley-Ebert; W D Stuart; C J Florio; P A Groen; S A Witt; T R Kimball; D P Witte; J A Harmony; B J Aronow
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

6.  Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis.

Authors:  Georgia Fousteri; Amy Dave; Bret Morin; Shaida Omid; Michael Croft; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2011-02-17       Impact factor: 7.094

7.  Inflammatory markers in a 2-year follow-up of coronary artery disease.

Authors:  Katarzyna Mizia-Stec; Zbigniew Gasior; Barbara Zahorska-Markiewicz; Michał Holecki; Paweł Kumor
Journal:  Heart Vessels       Date:  2006-09-29       Impact factor: 2.037

8.  Oral tolerization with cardiac myosin peptide (614-629) ameliorates experimental autoimmune myocarditis: role of STAT 6 genes in BALB/CJ mice.

Authors:  Patricia A Gonnella; Pedro J Del Nido; Francis X McGowan
Journal:  J Clin Immunol       Date:  2009-04-08       Impact factor: 8.317

9.  Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats.

Authors:  Pablo Nakagawa; Yunhe Liu; Tang-Dong Liao; Xiaojuan Chen; Germán E González; Kevin R Bobbitt; Derek Smolarek; Ed L Peterson; Ross Kedl; Xiao-Ping Yang; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-24       Impact factor: 4.733

10.  Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis.

Authors:  Urs Eriksson; Michael O Kurrer; Ivo Sonderegger; Giandomenica Iezzi; Anna Tafuri; Lukas Hunziker; Shinobu Suzuki; Kurt Bachmaier; Roland M Bingisser; Josef M Penninger; Manfred Kopf
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.